PDF(Pubmed)
Abstract：
Background: The purpose of this study was to analyze the major cardiovascular risk (CVR) factors and their trends in the study population. Methods: The results of subjects in the Polish Prospective Urban and Rural Epidemiological Study (PURE) study group were interpreted. CVR was calculated for each participant according to the Systematic Coronary Risk Evaluation (SCORE2) scale or the Systematic Coronary Risk Evaluation-Older Persons (SCORE2-OP) scale. Data from the beginning of the analysis (2013) and nine years later (2022) were included. In addition, the use of lipid-lowering therapy (LLT) and meeting the low-density lipoprotein cholesterol (LDL-c) target criterion at the beginning and end of the study were analyzed. Results: Patients in the high and very high CVR groups who had abnormal LDL-c results accounted for 64% and 91% of their group in 2013 and 70% and 92% in 2022, respectively. Conclusions: Regardless of age, patients using LLT at the start of the analysis had a greater increase in future CVR, especially if they had lipid abnormalities at the start of the study. This may be due to reverse causality and multimorbidity in these patients, highlighting the importance of appropriate treatment of lipid abnormalities.
摘要：
背景：这项研究的目的是分析研究人群中主要的心血管危险因素（CVR）及其趋势。方法：对波兰前瞻性城乡流行病学研究（PURE）研究组的受试者的结果进行解释。根据系统冠状动脉风险评估（SCORE2）量表或系统冠状动脉风险评估-老年人（SCORE2-OP）量表计算每位参与者的CVR。包括分析开始（2013年）和九年后（2022年）的数据。此外,分析了在研究开始和结束时使用降脂治疗(LLT)和符合低密度脂蛋白胆固醇(LDL-c)目标标准的情况.结果：高和极高CVR组中LDL-c异常结果的患者在2013年分别占该组的64％和91％，在2022年分别占70％和92％。结论：无论年龄大小，在分析开始时使用LLT的患者未来CVR有更大的增加，特别是如果他们在研究开始时就有脂质异常。这可能是由于这些患者的反向因果关系和多发病率，强调适当治疗脂质异常的重要性。
